{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T20:16:23Z","timestamp":1788984983004,"version":"build-2803163510"},"reference-count":77,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart Failure Clinics"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.hfc.2026.07.005","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T23:58:56Z","timestamp":1785455936000},"page":"451-462","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Fabry Disease"],"prefix":"10.1016","volume":"22","author":[{"given":"Emanuele","family":"Monda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Cirillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Rubino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Murredda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Caiazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetano","family":"Diana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Biagini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Limongelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.hfc.2026.07.005_bib1","doi-asserted-by":"crossref","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"10.1016\/j.hfc.2026.07.005_bib2","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.hfc.2021.07.005","article-title":"Diagnosis and management of cardiovascular involvement in fabry disease","volume":"18","author":"Rubino","year":"2022","journal-title":"Heart Fail Clin"},{"issue":"2","key":"10.1016\/j.hfc.2026.07.005_bib3","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCGEN.125.005361","article-title":"Cardiovascular morbidity and mortality in fabry disease","volume":"19","author":"Monda","year":"2026","journal-title":"Circ Genomic Precis Med"},{"issue":"3","key":"10.1016\/j.hfc.2026.07.005_bib4","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/ehjci\/jeaf285","article-title":"Sex-specific prognostic thresholds of left ventricular hypertrophy in fabry disease","volume":"27","author":"Meucci","year":"2026","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"6","key":"10.1016\/j.hfc.2026.07.005_bib5","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1093\/ehjqcco\/qcae052","article-title":"The Italian Fabry Disease Cardiovascular Registry (IFDCR)","volume":"10","author":"Limongelli","year":"2024","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"issue":"3","key":"10.1016\/j.hfc.2026.07.005_bib6","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1365-2362.2004.01309.x","article-title":"Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey","volume":"34","author":"Mehta","year":"2004","journal-title":"Eur J Clin Invest"},{"issue":"2","key":"10.1016\/j.hfc.2026.07.005_bib7","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s10741-014-9452-9","article-title":"Anderson-Fabry cardiomyopathy: prevalence, pathophysiology, diagnosis and treatment","volume":"20","author":"Putko","year":"2015","journal-title":"Heart Fail Rev"},{"issue":"8","key":"10.1016\/j.hfc.2026.07.005_bib8","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/j.jcmg.2018.03.020","article-title":"Proposed stages of myocardial phenotype development in fabry disease","volume":"12","author":"Nordin","year":"2019","journal-title":"JACC Cardiovasc Imaging"},{"issue":"7","key":"10.1016\/j.hfc.2026.07.005_bib9","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.jacc.2020.12.024","article-title":"Cardiac involvement in fabry disease: JACC review topic of the week","volume":"77","author":"Pieroni","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hfc.2026.07.005_bib10","article-title":"Sudden cardiac death risk prediction in Fabry disease: how many strings do we have on our bow?","volume":"418","author":"Monda","year":"2024","journal-title":"Int J Cardiol"},{"issue":"1","key":"10.1016\/j.hfc.2026.07.005_bib11","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human \u03b1-galactosidase a replacement therapy in Fabry\u2019s disease","volume":"345","author":"Eng","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hfc.2026.07.005_bib12","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ijcard.2019.06.073","article-title":"Prevalence and clinical significance of red flags in patients with hypertrophic cardiomyopathy","volume":"299","author":"Limongelli","year":"2020","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.hfc.2026.07.005_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2016.00007","article-title":"Electrocardiographic changes and arrhythmia in fabry disease","volume":"3","author":"Namdar","year":"2016","journal-title":"Front Cardiovasc Med"},{"issue":"12","key":"10.1016\/j.hfc.2026.07.005_bib14","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/j.echo.2013.09.005","article-title":"Systolic and diastolic function assessment in fabry disease patients using speckle-tracking imaging and comparison with conventional echocardiographic measurements","volume":"26","author":"Shanks","year":"2013","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1016\/j.hfc.2026.07.005_bib15","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.15420\/cfr.2023.06","article-title":"Cardiovascular involvement in Fabry\u2019s disease: new advances in diagnostic strategies, outcome prediction and management","volume":"9","author":"Monda","year":"2023","journal-title":"Card Fail Rev"},{"issue":"8","key":"10.1016\/j.hfc.2026.07.005_bib16","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1007\/s10554-020-01847-z","article-title":"Left ventricular radial strain impairment precedes hypertrophy in Anderson-Fabry disease","volume":"36","author":"Spinelli","year":"2020","journal-title":"Int J Cardiovasc Imaging"},{"key":"10.1016\/j.hfc.2026.07.005_bib17","article-title":"Cardiac MRI in Fabry disease","volume":"9","author":"Umer","year":"2022","journal-title":"Front Cardiovasc Med"},{"issue":"7","key":"10.1016\/j.hfc.2026.07.005_bib18","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1002\/ejhf.1960","article-title":"An expert consensus document on the management of cardiovascular manifestations of Fabry disease","volume":"22","author":"Linhart","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.hfc.2026.07.005_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijcard.2025.133219","article-title":"Electrocardiogram evolution in Anderson-Fabry disease patients during follow-up in relation to specific treatment and cardiac disease progression","volume":"431","author":"Parisi","year":"2025","journal-title":"Int J Cardiol"},{"issue":"12","key":"10.1016\/j.hfc.2026.07.005_bib20","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1093\/europace\/eur267","article-title":"Incidence and predictors of anti-bradycardia pacing in patients with Anderson-Fabry disease","volume":"13","author":"O\u2019Mahony","year":"2011","journal-title":"Europace"},{"issue":"3","key":"10.1016\/j.hfc.2026.07.005_bib21","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.echo.2025.11.012","article-title":"Patterns of left ventricular remodeling and outcomes in fabry disease","volume":"39","author":"Meucci","year":"2026","journal-title":"J Am Soc Echocardiogr"},{"issue":"10","key":"10.1016\/j.hfc.2026.07.005_bib22","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1093\/ejechocard\/jer112","article-title":"The endocardial binary appearance (\u2018binary sign\u2019) is an unreliable marker for echocardiographic detection of Fabry disease in patients with left ventricular hypertrophy","volume":"12","author":"Mundigler","year":"2011","journal-title":"Eur J Echocardiogr"},{"issue":"10","key":"10.1016\/j.hfc.2026.07.005_bib23","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.jacc.2022.06.027","article-title":"A roadmap to predict adverse outcome in fabry disease","volume":"80","author":"Monda","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.hfc.2026.07.005_bib24","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.jacc.2022.06.022","article-title":"Validated model for prediction of adverse cardiac outcome in patients with fabry disease","volume":"80","author":"Orsborne","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.hfc.2026.07.005_bib25","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s10741-023-10370-x","article-title":"Clinical staging of Anderson-Fabry cardiomyopathy: an operative proposal","volume":"29","author":"Del Franco","year":"2024","journal-title":"Heart Fail Rev"},{"issue":"15","key":"10.1016\/j.hfc.2026.07.005_bib26","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1016\/j.jacc.2023.07.026","article-title":"Prognostic implications of the extent of cardiac damage in patients with fabry disease","volume":"82","author":"Meucci","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.hfc.2026.07.005_bib27","article-title":"Evolution of cardiac damage staged with echocardiography in fabry disease","volume":"15","author":"Lillo","year":"2026","journal-title":"J Am Heart Assoc"},{"issue":"5","key":"10.1016\/j.hfc.2026.07.005_bib28","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1161\/STROKEAHA.110.579409","article-title":"Belgian Fabry study: prevalence of Fabry disease in a cohort of 1000 young patients with cerebrovascular disease","volume":"41","author":"Brouns","year":"2010","journal-title":"Stroke"},{"issue":"4","key":"10.1016\/j.hfc.2026.07.005_bib29","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/jhg.2010.18","article-title":"Cerebral hemorrhage in Fabry\u2019s disease","volume":"55","author":"Nakamura","year":"2010","journal-title":"J Hum Genet"},{"issue":"2","key":"10.1016\/j.hfc.2026.07.005_bib30","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/j.1468-1331.2010.03155.x","article-title":"Neuropsychiatric symptoms and brain structural alterations in Fabry disease","volume":"18","author":"Schermuly","year":"2011","journal-title":"Eur J Neurol"},{"issue":"447","key":"10.1016\/j.hfc.2026.07.005_bib31","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1651-2227.2005.tb02106.x","article-title":"FOS Investigators Natural history of the cerebrovascular complications of Fabry disease","volume":"94","author":"Mehta","year":"2005","journal-title":"Acta Paediatr Suppl"},{"issue":"3","key":"10.1016\/j.hfc.2026.07.005_bib32","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1161\/STROKEAHA.108.526293","article-title":"Stroke in fabry disease frequently occurs before diagnosis and in the absence of other clinical events: natural history data from the fabry registry","volume":"40","author":"Sims","year":"2009","journal-title":"Stroke"},{"issue":"2","key":"10.1016\/j.hfc.2026.07.005_bib33","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/1531-8249(200002)47:2<229::AID-ANA13>3.0.CO;2-T","article-title":"Profile of endothelial and leukocyte activation in Fabry patients","volume":"47","author":"DeGraba","year":"2000","journal-title":"Ann Neurol"},{"issue":"2","key":"10.1016\/j.hfc.2026.07.005_bib34","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s10545-015-9886-9","article-title":"Mannose receptor-mediated delivery of moss-made \u03b1-galactosidase A efficiently corrects enzyme deficiency in Fabry mice","volume":"39","author":"Shen","year":"2016","journal-title":"J Inherit Metab Dis"},{"issue":"5 Suppl","key":"10.1016\/j.hfc.2026.07.005_bib35","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/j.jpeds.2004.01.051","article-title":"Fabry disease in childhood","volume":"144","author":"Desnick","year":"2004","journal-title":"J Pediatr"},{"issue":"1","key":"10.1016\/j.hfc.2026.07.005_bib36","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/j.1651-2227.2006.tb02186.x","article-title":"Clinical manifestations of Fabry disease in children: data from the Fabry Outcome Survey","volume":"95","author":"Ramaswami","year":"2006","journal-title":"Acta Paediatr"},{"issue":"2","key":"10.1016\/j.hfc.2026.07.005_bib37","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1001\/archneur.1974.00490380068009","article-title":"Loss of small peripheral sensory neurons in Fabry disease. Histologic and morphometric evaluation of cutaneous nerves, spinal ganglia, and posterior columns","volume":"31","author":"Onishi","year":"1974","journal-title":"Arch Neurol"},{"issue":"455","key":"10.1016\/j.hfc.2026.07.005_bib38","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1651-2227.2007.00203.x","article-title":"Quantification of brain tissue alterations in Fabry disease using diffusion-tensor imaging","volume":"96","author":"Fellgiebel","year":"2007","journal-title":"Acta Paediatr"},{"issue":"3","key":"10.1016\/j.hfc.2026.07.005_bib39","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1159\/000322558","article-title":"Basilar artery diameter is a potential screening tool for Fabry disease in young stroke patients","volume":"31","author":"Fellgiebel","year":"2011","journal-title":"Cerebrovasc Dis"},{"issue":"2","key":"10.1016\/j.hfc.2026.07.005_bib40","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1136\/bjo.2006.100602","article-title":"Ocular manifestations of Fabry\u2019s disease: data from the Fabry Outcome Survey","volume":"91","author":"Sodi","year":"2007","journal-title":"Br J Ophthalmol"},{"issue":"12","key":"10.1016\/j.hfc.2026.07.005_bib41","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.3174\/ajnr.A5420","article-title":"Redefining the pulvinar sign in fabry disease","volume":"38","author":"Cocozza","year":"2017","journal-title":"AJNR Am J Neuroradiol"},{"issue":"5","key":"10.1016\/j.hfc.2026.07.005_bib42","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1007\/s00415-008-0786-x","article-title":"The pulvinar sign: frequency and clinical correlations in Fabry disease","volume":"255","author":"Burlina","year":"2008","journal-title":"J Neurol"},{"issue":"2","key":"10.1016\/j.hfc.2026.07.005_bib43","doi-asserted-by":"crossref","first-page":"497","DOI":"10.3390\/neurolint14020041","article-title":"Pulvinar sign, stroke and their relationship with fabry disease: a systematic review and metanalysis","volume":"14","author":"Ort\u00edz","year":"2022","journal-title":"Neurol Int"},{"issue":"3","key":"10.1016\/j.hfc.2026.07.005_bib44","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ymgme.2011.06.021","article-title":"Cystatin C and NT-proBNP as prognostic biomarkers in Fabry disease","volume":"104","author":"Torralba-Cabeza","year":"2011","journal-title":"Mol Genet Metab"},{"issue":"1","key":"10.1016\/j.hfc.2026.07.005_bib45","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1086\/504601","article-title":"High incidence of later-onset Fabry disease revealed by newborn screening","volume":"79","author":"Spada","year":"2006","journal-title":"Am J Hum Genet"},{"issue":"6","key":"10.1016\/j.hfc.2026.07.005_bib46","article-title":"Impact of GLA variant classification on the estimated prevalence of fabry disease: a systematic review and meta-analysis of screening studies","volume":"16","author":"Monda","year":"2023","journal-title":"Circ Genom Precis Med"},{"key":"10.1016\/j.hfc.2026.07.005_bib47","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ijcard.2022.03.050","article-title":"Diagnosis and management of rare cardiomyopathies in adult and paediatric patients. A position paper of the Italian Society of Cardiology (SIC) and Italian Society of paediatric cardiology (SICP)","volume":"357","author":"Limongelli","year":"2022","journal-title":"Int J Cardiol"},{"issue":"31","key":"10.1016\/j.hfc.2026.07.005_bib48","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1093\/eurheartj\/ehaf026","article-title":"Hypertrophic cardiomyopathy: prevalence of disease-specific red flags","volume":"46","author":"Maurizi","year":"2025","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.hfc.2026.07.005_bib49","article-title":"Development of a smartphone-based app to support the differential diagnosis in patients with primary left ventricular hypertrophy","volume":"7","author":"Maurizi","year":"2026","journal-title":"Eur Heart J Digit Health"},{"key":"10.1016\/j.hfc.2026.07.005_bib50","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.838200","article-title":"Importance of echocardiography and clinical \u201cRed Flags\u201d in guiding genetic screening for fabry disease","volume":"9","author":"Citro","year":"2022","journal-title":"Front Cardiovasc Med"},{"issue":"1","key":"10.1016\/j.hfc.2026.07.005_bib51","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1186\/s13023-024-03131-y","article-title":"A systematic literature review on the health-related quality of life and economic burden of Fabry disease","volume":"19","author":"Jovanovic","year":"2024","journal-title":"Orphanet J Rare Dis"},{"issue":"8","key":"10.1016\/j.hfc.2026.07.005_bib52","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.123.010687","article-title":"Targeted therapies in pediatric and adult patients with hypertrophic heart disease: from molecular pathophysiology to personalized medicine","volume":"16","author":"Monda","year":"2023","journal-title":"Circ Heart Fail"},{"issue":"10","key":"10.1016\/j.hfc.2026.07.005_bib53","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/s41569-025-01183-6","article-title":"Tailored therapeutics for cardiomyopathies","volume":"22","author":"Bakalakos","year":"2025","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.hfc.2026.07.005_bib54","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13023-015-0253-6","article-title":"Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document","volume":"10","author":"Biegstraaten","year":"2015","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"10.1016\/j.hfc.2026.07.005_bib55","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/cge.13546","article-title":"Consensus recommendations for diagnosis, management and treatment of Fabry disease in paediatric patients","volume":"96","author":"Germain","year":"2019","journal-title":"Clin Genet"},{"issue":"12","key":"10.1016\/j.hfc.2026.07.005_bib56","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/j.1365-2362.2004.01424.x","article-title":"Fabry disease: overall effects of agalsidase alfa treatment","volume":"34","author":"Beck","year":"2004","journal-title":"Eur J Clin Invest"},{"issue":"6","key":"10.1016\/j.hfc.2026.07.005_bib57","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1136\/jmg-2023-109445","article-title":"Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study","volume":"61","author":"Wallace","year":"2024","journal-title":"J Med Genet"},{"issue":"5","key":"10.1016\/j.hfc.2026.07.005_bib58","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1136\/jmedgenet-2014-102797","article-title":"Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with fabry disease","volume":"52","author":"Germain","year":"2015","journal-title":"J Med Genet"},{"key":"10.1016\/j.hfc.2026.07.005_bib59","doi-asserted-by":"crossref","first-page":"3561","DOI":"10.2147\/DDDT.S313789","article-title":"Prompt agalsidase alfa therapy initiation is associated with improved renal and cardiovascular outcomes in a Fabry Outcome Survey analysis","volume":"15","author":"Hughes","year":"2021","journal-title":"Drug Des Devel Ther"},{"issue":"2","key":"10.1016\/j.hfc.2026.07.005_bib60","doi-asserted-by":"crossref","first-page":"77","DOI":"10.7326\/0003-4819-146-2-200701160-00148","article-title":"Agalsidase-beta therapy for advanced fabry disease: a randomized trial","volume":"146","author":"Banikazemi","year":"2007","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.hfc.2026.07.005_bib61","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/gim.2016.117","article-title":"Switch to agalsidase alfa after shortage of agalsidase beta in Fabry disease: a systematic review and meta-analysis of the literature","volume":"19","author":"Pisani","year":"2017","journal-title":"Genet Med"},{"issue":"5","key":"10.1016\/j.hfc.2026.07.005_bib62","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/jmedgenet-2017-104863","article-title":"Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study","volume":"55","author":"Arends","year":"2018","journal-title":"J Med Genet"},{"issue":"3","key":"10.1016\/j.hfc.2026.07.005_bib63","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.ymgme.2011.03.022","article-title":"Response of women with Fabry disease to enzyme replacement therapy: comparison with men, using data from FOS--the Fabry Outcome Survey","volume":"103","author":"Hughes","year":"2011","journal-title":"Mol Genet Metab"},{"issue":"12","key":"10.1016\/j.hfc.2026.07.005_bib64","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1016\/j.clinthera.2020.10.007","article-title":"Effects of baseline left ventricular hypertrophy and decreased renal function on cardiovascular and renal outcomes in patients with fabry disease treated with agalsidase Alfa: a Fabry Outcome Survey Study","volume":"42","author":"Feriozzi","year":"2020","journal-title":"Clin Ther"},{"issue":"9706","key":"10.1016\/j.hfc.2026.07.005_bib65","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1016\/S0140-6736(09)61493-8","article-title":"Enzyme replacement therapy with agalsidase alfa in patients with Fabry\u2019s disease: an analysis of registry data","volume":"374","author":"Mehta","year":"2009","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.hfc.2026.07.005_bib66","doi-asserted-by":"crossref","DOI":"10.1148\/ryct.230154","article-title":"Effects of enzyme replacement therapy on cardiac MRI findings in fabry disease: a systematic review and meta-analysis","volume":"6","author":"Figliozzi","year":"2024","journal-title":"Radiol Cardiothorac Imaging"},{"issue":"6","key":"10.1016\/j.hfc.2026.07.005_bib67","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.2353\/ajpath.2008.070576","article-title":"Myofilament degradation and dysfunction of human cardiomyocytes in fabry disease","volume":"172","author":"Chimenti","year":"2008","journal-title":"Am J Pathol"},{"issue":"21","key":"10.1016\/j.hfc.2026.07.005_bib68","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in fabry disease a randomized controlled trial","volume":"285","author":"Schiffmann","year":"2001","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.hfc.2026.07.005_bib69","first-page":"33","article-title":"Effect of reduced agalsidase beta dosage in fabry patients: the Australian experience","volume":"3","author":"Ghali","year":"2012","journal-title":"JIMD Rep"},{"key":"10.1016\/j.hfc.2026.07.005_bib70","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jocn.2019.03.064","article-title":"Fabry\u2019s disease and stroke: effectiveness of enzyme replacement therapy (ERT) in stroke prevention, a review with meta-analysis","volume":"65","author":"Sheng","year":"2019","journal-title":"J Clin Neurosci"},{"issue":"1","key":"10.1016\/j.hfc.2026.07.005_bib71","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ymgme.2008.10.004","article-title":"A retrospective analysis of the potential impact of IgG antibodies to agalsidase beta on efficacy during enzyme replacement therapy for Fabry disease","volume":"96","author":"B\u00e9nichou","year":"2009","journal-title":"Mol Genet Metab"},{"issue":"4","key":"10.1016\/j.hfc.2026.07.005_bib72","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1111\/j.1523-1755.2004.00924.x","article-title":"Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta","volume":"66","author":"Linthorst","year":"2004","journal-title":"Kidney Int"},{"issue":"9","key":"10.1016\/j.hfc.2026.07.005_bib73","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1038\/s41436-019-0451-z","article-title":"Efficacy of the pharmacologic chaperone migalastat in a subset of male patients with the classic phenotype of Fabry disease and migalastat-amenable variants: data from the phase 3 randomized, multicenter, double-blind clinical trial and extension study","volume":"21","author":"Germain","year":"2019","journal-title":"Genet Med"},{"issue":"4","key":"10.1016\/j.hfc.2026.07.005_bib74","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1136\/jmedgenet-2016-104178","article-title":"Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study","volume":"54","author":"Hughes","year":"2017","journal-title":"J Med Genet"},{"issue":"2","key":"10.1016\/j.hfc.2026.07.005_bib75","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/cpt.1832","article-title":"Treatment of Fabry\u2019s disease with Migalastat: outcome from a Prospective Observational Multicenter Study (FAMOUS)","volume":"108","author":"Lenders","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.hfc.2026.07.005_bib76","article-title":"Long-term follow-up of renal function in patients treated with migalastat for Fabry disease","volume":"28","author":"Bichet","year":"2021","journal-title":"Mol Genet Metab Rep"},{"issue":"4","key":"10.1016\/j.hfc.2026.07.005_bib77","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/cpt.790","article-title":"Lucerastat, an iminosugar for substrate reduction therapy: tolerability, pharmacodynamics, and pharmacokinetics in patients with fabry disease on enzyme replacement","volume":"103","author":"Gu\u00e9rard","year":"2018","journal-title":"Clin Pharmacol Ther"}],"container-title":["Heart Failure Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551713626000486?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551713626000486?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T19:54:55Z","timestamp":1788983695000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551713626000486"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":77,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S1551713626000486"],"URL":"https:\/\/doi.org\/10.1016\/j.hfc.2026.07.005","relation":{},"ISSN":["1551-7136"],"issn-type":[{"value":"1551-7136","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fabry Disease","name":"articletitle","label":"Article Title"},{"value":"Heart Failure Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hfc.2026.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}